ROI included sites that are commonly mutated in both primary and metastatic tumors (e.g., PIK3CA and TP53) as well as sites of putative metastatic driver mutations that we previously identified as specific to the metastatic tumor by WES (e.g., ESR1) [7]. This evidence concerns the gene ESR1 and metastatic neoplasm.